Evidence map›Paper›PMID 34743187›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2022

Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.

Kelly A Devereaux, Julianna J Weiel, Jennifer Pors, David F Steiner, Chandler Ho, Vivek Charu, Carlos J Suarez, Malte Renz, Elisabeth Diver, Amer Karam and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. New histopathological and molecular findings in gynecological cancers.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. The game-changing impact ofFrontiers in oncology · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kelly A DevereauxDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Julianna J WeielDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Jennifer PorsDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
David F SteinerDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Chandler HoDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Vivek CharuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Carlos J SuarezDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Malte RenzDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Elisabeth DiverDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Amer KaramDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Babak LitkouhiDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Oliver DorigoDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Elizabeth A KiddStanford Women's Cancer Center and Stanford Cancer Institute, Stanford, CA, USA.
Eric J YangDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Ann K FolkinsDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Teri A LongacreDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Brooke E HowittDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA. bhowitt@stanford.edu.ORCID 0000-0002-0309-6680

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

The comprehensive genomic analysis of endometrial carcinoma (EC) by The Cancer Genome Atlas (TCGA) led to the discovery of four distinct and prognostically significant molecular subgroups. Molecular classification has the potential to improve risk-stratification when integrated with clinicopathologic features and has recently been included in national and international patient management EC guidelines. Thus, the adoption of molecular classification into routine pathologic and clinical practice is likely to grow significantly in the upcoming years. Establishing an efficient and standardized workflow for performing molecular classification on ECs, and reporting both the molecular and histologic findings in an integrative manner, is imperative. Here we describe our effort to implement rapid and routine molecular classification on all ECs diagnosed at our institution. To this effect, we performed immunohistochemistry as a surrogate marker for identifying genetic and/or epigenetic alterations in DNA mismatch repair (e.g., MLH1, PMS2, MSH6, MSH2), and TP53 genes. In addition, we have developed and employed a single-gene POLE SNaPshot assay, which is a rapid and analytically sensitive method for detecting select POLE exonuclease domain mutations (EDMs). We report our molecular testing workflow and integrative reporting system as well as the clinicopathologic and molecular features of 310 ECs that underwent routine molecular classification at our institution. The 310 ECs were molecularly classified as follows: 15 (5%) POLE mutant (POLEmut), 79 (25%) mismatch repair-deficient (MMRd), 135 (44%) no specific molecular profile (NSMP), and 81 (26%) p53 abnormal (p53abnl). This work provides an initial framework for implementing routine molecular classification of ECs.

Indexed as

Endometrial NeoplasmsBiomarkers, TumorDNA Mismatch RepairFemaleGenes, p53HumansImmunohistochemistryMutationProspective StudiesBiomarkers, Tumor

Identifiers

PMID34743187
PMCPMC12817303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.